TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03516916

Intervention type: OTHER
Intervention: Questionnaires on HRQoL and sociodemography
Description: All patients are asked to answer a panel of questionnaires to test validity and reliability of the Colostomy Impact Score.

Intervention type: OTHER
Intervention: Questionnaires on HRQoL and sociodemography
Description: All patients are asked to answer a panel of questionnaires to test validity and reliability of the Colostomy Impact Score.

Intervention type: OTHER
Intervention: Questionnaires on HRQoL and sociodemography
Description: All patients are asked to answer a panel of questionnaires to test validity and reliability of the Colostomy Impact Score.

Intervention type: OTHER
Intervention: Questionnaires on HRQoL and sociodemography
Description: All patients are asked to answer a panel of questionnaires to test validity and reliability of the Colostomy Impact Score.

Intervention type: OTHER
Intervention: Questionnaires on HRQoL and sociodemography
Description: All patients are asked to answer a panel of questionnaires to test validity and reliability of the Colostomy Impact Score.

Intervention type: OTHER
Intervention: Questionnaires on HRQoL and sociodemography
Description: All patients are asked to answer a panel of questionnaires to test validity and reliability of the Colostomy Impact Score.

Intervention type: OTHER
Intervention: Questionnaires on HRQoL and sociodemography
Description: All patients are asked to answer a panel of questionnaires to test validity and reliability of the Colostomy Impact Score.

Intervention type: OTHER
Intervention: Questionnaires on HRQoL and sociodemography
Description: All patients are asked to answer a panel of questionnaires to test validity and reliability of the Colostomy Impact Score.

Intervention type: OTHER
Intervention: Questionnaires on HRQoL and sociodemography
Description: All patients are asked to answer a panel of questionnaires to test validity and reliability of the Colostomy Impact Score.

Intervention type: OTHER
Intervention: Questionnaires on HRQoL and sociodemography
Description: All patients are asked to answer a panel of questionnaires to test validity and reliability of the Colostomy Impact Score.
Study: NCT01343056

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Office Staff Support
Description: The intervention includes the Office staff of primary care practices trained to provide diabetes support for behavioral goal setting were tasked to follow up with patients via phone following completion of diabetes self-management education.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Peer Support
Description: Community peers trained to provide diabetes support for behavioral goal setting were tasked to follow up with patients via phone following completion of diabetes self-management education.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Support
Description: Diabetes educators provided patient follow up for behavioral goal setting support according to traditional clinical guidelines following completion of diabetes self-management.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educator Support
Description: Diabetes educators provided patient follow up for behavioral goal setting support that was problem-focused and patient centered.
Study: NCT04606953

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Process Training (APT-II)
Description: The exercises target different attentional components and working memory in the auditory-visual modalities. They are of increasing difficulty while being adapted to the profile of each patient in order to maximize the effects on cognitive reserve. During the sessions, the emphasis is on generalizing the gains to the most problematic daily activities in order to reduce the impact of cognitive disorders in patients' daily life.
Study: NCT01285375

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CDC solution
Description: 2 ml of CDC 12/mg/ml is added to 1 l of UW solution. 500 ml of of this solution is used for flushing the kidney allograft prior to transplantation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: UW-solution
Description: 500 ml of UW solution is used for flushing the kidney allograft prior to transplantation
Study: NCT06113263

Intervention type: PROCEDURE
Intervention: Anterior cervical decompression surgery
Description: The aim of the surgery is to reduce the compression of the affected nerve. With anterior cervical decompression surgery this is achieved by removing the disc and osteophytes.

Intervention type: PROCEDURE
Intervention: Posterior cervical foraminotomy with or without laminectomy
Description: The aim of the surgery is to reduce the compression of the affected nerve. With posterior cervical decompression surgery more space is created for the nerve by widening the foramina where the nerve exits
Study: NCT04188405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ponatinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study: NCT03319693

Intervention type: GENETIC
Intervention: Somatic Genetic
Description: NGS analysis
Study: NCT02983955

Intervention type: DEVICE
Group type: OTHER
Intervention: UPnRIDE Powered Wheelchair
Description: The UPnRIDE Powered Wheelchair device is a product which changes people position from sitting to standing and standing to sitting. The product provides indoor and outdoor mobility.
Study: NCT05051241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GFH018
Description: Subjects will receive GFH018 orally at different dose levels following twice daily, 14-day on/14-day off regimen. Other dose regimens, eg 7d-on/7d-off will also be considered to be explored when the safety/tolerability is confirmed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GFH018
Description: Subjects will receive GFH018 orally at different dose levels following twice daily, 14-day on/14-day off regimen. Other dose regimens, eg 7d-on/7d-off will also be considered to be explored when the safety/tolerability is confirmed.
Study: NCT04108884

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: App measurement
Description: App measurement twice a day in the first two weeks after enrollment and twice a week (on different days) from the third week onward and whenever patients feel palpitations

Intervention type: DEVICE
Group type: OTHER
Intervention: App measurement
Description: App measurement twice a day in the first two weeks after enrollment and twice a week (on different days) from the third week onward and whenever patients feel palpitations

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 14 day Holter ECG
Description: 14 day moblie patch Holter ECG for AF confirmation
Study: NCT01382901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric Carboxymaltose (FCM)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01642693

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low power laser in teeth after intrusive movement
Description: Low power laser was aplied to premolar teeth under an intrusive movement to study histological changes and root resorption

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simulated laser in teeth with intrusive movements
Description: Simulated laser in teeth with intrusive movements for histological and root resorption changes
Study: NCT03500887

Intervention type: DEVICE
Group type: OTHER
Intervention: intragastric bag

Intervention type: DEVICE
Group type: OTHER
Intervention: intragastric bag
Study: NCT05051241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GFH018
Description: Subjects will receive GFH018 orally at different dose levels following twice daily, 14-day on/14-day off regimen. Other dose regimens, eg 7d-on/7d-off will also be considered to be explored when the safety/tolerability is confirmed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GFH018
Description: Subjects will receive GFH018 orally at different dose levels following twice daily, 14-day on/14-day off regimen. Other dose regimens, eg 7d-on/7d-off will also be considered to be explored when the safety/tolerability is confirmed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GFH018
Description: Subjects will receive GFH018 orally at different dose levels following twice daily, 14-day on/14-day off regimen. Other dose regimens, eg 7d-on/7d-off will also be considered to be explored when the safety/tolerability is confirmed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GFH018
Description: Subjects will receive GFH018 orally at different dose levels following twice daily, 14-day on/14-day off regimen. Other dose regimens, eg 7d-on/7d-off will also be considered to be explored when the safety/tolerability is confirmed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GFH018
Description: Subjects will receive GFH018 orally at different dose levels following twice daily, 14-day on/14-day off regimen. Other dose regimens, eg 7d-on/7d-off will also be considered to be explored when the safety/tolerability is confirmed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GFH018
Description: Subjects will receive GFH018 orally at different dose levels following twice daily, 14-day on/14-day off regimen. Other dose regimens, eg 7d-on/7d-off will also be considered to be explored when the safety/tolerability is confirmed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GFH018
Description: Subjects will receive GFH018 orally at different dose levels following twice daily, 14-day on/14-day off regimen. Other dose regimens, eg 7d-on/7d-off will also be considered to be explored when the safety/tolerability is confirmed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GFH018
Description: Subjects will receive GFH018 orally at different dose levels following twice daily, 14-day on/14-day off regimen. Other dose regimens, eg 7d-on/7d-off will also be considered to be explored when the safety/tolerability is confirmed.
Study: NCT03394274

Intervention type: OTHER
Intervention: restrictive and liberal transfusion
Description: hemoglobin threshold value was accepted 8g/dl. restrictive blood transfusion group was defined that if perioperative transfusion was started equal or under hemoglobin level 8 g / dL. Liberal blood transfusion group was defined as perioperative transfusion was started over hemoglobin level 8 g / dL .
Study: NCT02399267

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Once daily screening
Description: RTs will screen invasively ventilated patients between approximately 06:00 - 08:00 hours daily. To pass the 'readiness to wean screen' and undergo an SBT, specific criteria must be met.
Study: NCT00552617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Description: After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV.~Maintenance doses of 0.1-0.2 mg/kg rocuronium IV could be administered if necessary.
Study: NCT02399267

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Twice daily screening
Description: In the 'at least twice daily' screening arm patients will be screened at a minimum between approximately 6:00-8:00 hours and 13:00-15:00 hours daily. To pass the 'readiness to wean screen' and undergo an SBT, specific criteria must be met.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PS SBTs
Description: Patients are assigned a SBT technique. All SBTs for these patients must be conducted on PS =\< 8 cm H2O with PEEP =\< 5 cm H2O.
Study: NCT00552617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Description: After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV.~Maintenance doses of 0.1-0.2 mg/kg rocuronium IV could be administered if necessary.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Description: After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV.~Maintenance doses of 0.1-0.2 mg/kg rocuronium IV could be administered if necessary.
Study: NCT02399267

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: T-piece SBTs
Description: Patients are assigned a SBT technique. All SBTs for these patients must be conducted with T-piece.
Study: NCT00614211

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Abdominal Radical Hysterectomy
Description: In a radical hysterectomy the uterus, the upper one to two centimetres of the vagina and the soft tissues around the cervix are excised.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total Laparoscopic or Robotic Radical Hysterectomy
Description: In a radical hysterectomy the uterus, the upper one to two centimetres of the vagina and the soft tissues around the cervix are excised.
Study: NCT02970344

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Coping Skills Training (DCST)
Description: Diabetes Coping Skills Training (DCST) consist of twelve 50 minutes sessions delivered over 6 months using a faded contact model ( 6 weekly session, 3 biweekly sessions and 3 monthly sessions)
Study: NCT01579344

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Radioiodine therapy
Description: Radioiodine therapy with NaI131
Study: NCT02736539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBS 2004 (galacto-oligosaccharides)
Description: CBS 2004 active treatment
Study: NCT00552617

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rocuronium
Description: After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV.~Maintenance doses of 0.1-0.2 mg/kg rocuronium IV could be administered if necessary.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vecuronium
Description: After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV. Maintenance doses of 0.02-0.03 mg/kg vecuronium IV could be administered if necessary.
Study: NCT02736539

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo treatment
Study: NCT03737370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel will be administered every 2 weeks (on Day 1 and Day 15 of a 28 day cycle). Fractionated dosing dependent on cohort.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel will be administered every 2 weeks (on Day 1 and Day 15 of a 28 day cycle). Fractionated dosing dependent on cohort.
Study: NCT00552617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vecuronium
Description: After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV. Maintenance doses of 0.02-0.03 mg/kg vecuronium IV could be administered if necessary.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vecuronium
Description: After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV. Maintenance doses of 0.02-0.03 mg/kg vecuronium IV could be administered if necessary.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vecuronium
Description: After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV. Maintenance doses of 0.02-0.03 mg/kg vecuronium IV could be administered if necessary.
Study: NCT03737370

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radium 223
Description: Radium 223 will be delivered every 28 days (on day 1) for 6 cycles.
Study: NCT00552617

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vecuronium
Description: After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV. Maintenance doses of 0.02-0.03 mg/kg vecuronium IV could be administered if necessary.
Study: NCT00295308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine
Description: clonidine up to 0.3 mg/day oral
Study: NCT01046643

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol (E2)
Description: One Estradiol capsule (1mg) once a day, at the same time each day, for 90 days; followed by one Progesterone (200mg) once a day, at the same time each day, for 10 days to slough endometrial lining; followed by one Placebo capsule once a day, at the same time each day, for 90 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol (E2)
Description: One Estradiol capsule (1mg) once a day, at the same time each day, for 90 days; followed by one Progesterone (200mg) once a day, at the same time each day, for 10 days to slough endometrial lining; followed by one Placebo capsule once a day, at the same time each day, for 90 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone (P10) x90
Description: One Progesterone capsule (200mg) once a day, at the same time each day, for 90 days; followed by one Placebo capsule (to mirror Progesterone capsule to slough endometrial lining in Estradiol recipients) once a day, at the same time each day, for 10 days ; followed by one Placebo capsule once a day, at the same time each day, for 90 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone (P10) x90
Description: One Progesterone capsule (200mg) once a day, at the same time each day, for 90 days; followed by one Placebo capsule (to mirror Progesterone capsule to slough endometrial lining in Estradiol recipients) once a day, at the same time each day, for 10 days ; followed by one Placebo capsule once a day, at the same time each day, for 90 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone (P10) x10
Description: One Progesterone (200mg) capsule once a day for 10 days, to slough endometrial lining for patients taking Estradiol. Patients taking Progesterone will take an equivalent Placebo capsule during this time period.
Study: NCT00295308

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral capsules daily
Study: NCT01052038

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo administration
Description: Placebo administration
Study: NCT01046643

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone (P10) x10
Description: One Progesterone (200mg) capsule once a day for 10 days, to slough endometrial lining for patients taking Estradiol. Patients taking Progesterone will take an equivalent Placebo capsule during this time period.
Study: NCT01052038

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 0.05mg/kr administration
Description: Dexamethasone 0.05mg/kr administered in 100ml of sterile saline solution prior to the start of surgery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 0.1mg/kg
Description: Dexamethasone 0.1mg/kg administered in 100ml of sterile saline solution prior to the beginning of surgery.
Study: NCT01408589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine, Strattera
Description: Atomoxetine at 0, 40, 60, 80 mg/day was given for 5 days, all subjects took two capsules per day for 5 days; all active dose groups received 40 mg/day for first 3 days and where then dose escalated to dosage group assigned.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine, Strattera
Description: Atomoxetine at 0, 40, 60, 80 mg/day was given for 5 days, all subjects took two capsules per day for 5 days; all active dose groups received 40 mg/day for first 3 days and where then dose escalated to dosage group assigned.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine, Strattera
Description: Atomoxetine at 0, 40, 60, 80 mg/day was given for 5 days, all subjects took two capsules per day for 5 days; all active dose groups received 40 mg/day for first 3 days and where then dose escalated to dosage group assigned.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atomoxetine, Strattera
Description: Atomoxetine at 0, 40, 60, 80 mg/day was given for 5 days, all subjects took two capsules per day for 5 days; all active dose groups received 40 mg/day for first 3 days and where then dose escalated to dosage group assigned.
Study: NCT00744536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide and melphalan
Description: Lenalidomide (Revlimid) 10 mg po daily for 21d/28 Melphalan (Melphalan) 2 mg po daily for 21d/28
Study: NCT04574544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc Supplementation
Description: The 25 supplemented children had received an oral zinc supplement per day for 14 days and had no dietary restrictions.
Study: NCT02833558

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PuraStat®
Description: PuraStat® gel is applied through a safe catheter delivery system (via endoscope) over the bleeding point

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Electrocautery
Description: Electrocautery (coagulation current) to stop bleeding during ESD
Study: NCT01921725

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hydrophilic-based dressing (KoCarbonTM)
Description: BCT Hydrophilic Wound Dressing consists of PET non-woven, activated carbon fiber (ACF) cloth and PE film. The PET non-woven is vapor permeable to allow air exchange for the wound. The absorbent ACF absorbs exudate, bacteria and odor to create an effective barrier. Furthermore, far infrared ray (FIR) emitted from ACF accelerates blood circulation and metabolism to reduce healing period. The PE film helps to minimize wound trauma at dressing changes.
Study: NCT02733458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GELAD
Description: Gemcitabine, 1.0g/m2/d IV, day 1 Etoposide, 60mg/m2 IV, day 1 to day 3 Dexamethasone, 40mg/d IV, day 1 to day 4 Pegaspargase, 2000IU/m2/d IM, day 4

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Radiotherapy: 50-56Gy
Study: NCT01068795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enoxaparin
Description: enoxaparin dosage will be adjusted according to anti-factor Xa plasma levels
Study: NCT04574544

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition education of mothers
Description: Nutritional information was delivered to each mother to facilitate a change in bad eating habits observed, improve knowledge, attitudes and skills of mothers on child nutrition. The anthropometric and biochemistry parameters of children were taken before and after the maternal nutrition education
Study: NCT03112616

Intervention type: OTHER
Intervention: Vibration sessions
Description: The patients will undergo a program of 10 sessions of vibrations of the neck muscle, each of 10 minutes, during a period of 15 days at the rate of one session per day.

Intervention type: OTHER
Intervention: Vibration sessions
Description: The patients will undergo a program of 10 sessions of vibrations of the neck muscle, each of 10 minutes, during a period of 15 days at the rate of one session per day.